Eating Disorders Are Up 71% — and GLP-1s Could Make Things Worse

From 1990 to 2023, the global incidence of anorexia nervosa and bulimia nervosa rose by 71%. That number arrives at an awkward moment. Over the same recent decade, GLP-1 weight-loss drugs have become biotech's biggest story — and some clinical psychologists warn these medications could act as a catalyst for eating disorders.

That warning deserves to be taken seriously, and not only because of the numbers. It lands in a culture that already struggles to see what these drugs actually do. A headline says "GLP-1." A chart shows a receptor. A diagram flattens a molecule onto a screen. None of it conveys scale, binding, or mechanism — the things that turn a mechanism into an event you can understand.

That gap is exactly what NexoPeek was built to close.

Flat Diagrams Miss the Molecule

The problem, as NexoPeek's own framing puts it, is that we don't "see" enough of where and how a drug acts. Flat charts lose the size of a molecule and the way it binds. When the subject is a medication that influences appetite and eating behavior, that loss isn't cosmetic. It's the difference between reading a label and understanding a process.

NexoPeek, by Seven Sportz, is a Meta Quest experience that turns a headset into a molecular laboratory. Instead of looking at a receptor diagram pinned to a 2D monitor, you step inside the biology. Twelve narrated tours are organized across six axes: Biotechnology Basics, Foundations of Life, Pathways & Interactions, Medicines in Action, Genetic Technologies, and Green Biotech.

The tours are concrete. You walk inside hemoglobin and watch oxygen molecules bind. You follow glycolysis as glucose breaks down. You see aspirin block the COX enzyme. You witness CRISPR-Cas9 edit DNA. Each is a narrated tour, not an animation loop — a guided pass through a mechanism that is normally reduced to an arrow on a slide.

Why Seeing Mechanism Matters Now

The eating-disorder hook and the GLP-1 boom are usually discussed as a policy question: should these drugs be prescribed more carefully, monitored more closely, talked about differently? Those are real questions. But underneath them sits a simpler one — do the people prescribing, taking, and debating these drugs actually understand the biology they're intervening in?

Some clinical psychologists fear GLP-1s could become a catalyst for eating disorders. Whatever the eventual evidence shows, the fear itself is a signal that the conversation is running ahead of comprehension. Abstraction is comfortable. It lets us argue about molecules we have never really pictured.

NexoPeek doesn't answer the clinical question. It doesn't claim to. What it does is remove one excuse for not looking. When you have stood inside a binding event, "the drug acts on a receptor" stops being a sentence you repeat and becomes something closer to a place you've been.

From Headline to Handheld Mechanism

Consider the arc of a single viewer. They see the 71% headline. They see a GLP-1 pen on a desk in a psychiatrist's office. Then, in the headset, they step into the molecular world where such drugs operate — the same world that a receptor diagram, flattened and broken on a monitor, fails to convey.

That's the bridge NexoPeek offers: not a verdict on GLP-1s, but a way to see the biology that the verdict depends on. Twelve narrated tours. Six axes. A molecular laboratory you wear.

The rise in eating disorders is a serious trend. The GLP-1 era is a serious shift. Both deserve more than a headline and a flat chart. They deserve a look at the mechanism itself — up close, at scale, and in motion.

Step inside the molecule. Try NexoPeek on Meta Quest:
https://www.meta.com/experiences/nexopeek/1453797551140347/